Wed.Jan 08, 2025

article thumbnail

How to Sell an IT Business: Everything You Need to Know in Five Minutes

Sun Acquisitions

Selling an IT services businessis a crucial decision. Before you take the next step, lets walk through some key factors to consider. In business as in life, two things are key: Timing and preparation. Selling a business in Information Technology (IT) or within the Managed Services Provider (MSP) space means getting both of these things right. Unfortunately, it’s not as easy as punching “sell IT business” into Google and letting the offers roll right in.

article thumbnail

Is This the Last Gasp? FTC Makes One Last Plea to Get Its Noncompete Ban Back on Track

BVR

In a last ditch effort to revive its covenant not to compete ban, the Lina Kahn-led FTC is asking a federal appeals court to overturn a federal district court ruling that halted the FTC ban.

100
100
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Why Brazilian farmers are doubling down on productivity

Mckinsey and Company

Challenging times in agriculture have reinforced the importance of productivity for profitability, a McKinsey survey of Brazilian farmers found.

96
article thumbnail

Constellation Energy in talks to buy Calpine in big US power sector deal

Financial Times M&A

Takeover talks come amid surge in demand linked to rollout of artificial intelligence technologies

article thumbnail

How to Leverage Intent Data for Better Outcomes

Speaker: Susan Spencer, Principal of Spencer Communications

Intent signal data can go a long way toward shortening sales cycles and closing more deals. The challenge is deciding which is the best type of intent data to help your company meet its sales and marketing goals. In this webinar, Susan Spencer, fractional CMO and principal of Spencer Communications, will unpack the differences between contact-level and company-level intent signals.

article thumbnail

Operational excellence in biopharma research and early development

Mckinsey and Company

Leading companies are revamping research and early development to curb lengthy drug development timelines and rising costs.

65
article thumbnail

BlackRock private equity fund takes more than $600mn hit on investment

Financial Times M&A

Alacritys restructuring puts it under control of private credit lenders including Antares, Blue Owl, KKR and Goldman

Equity 86

More Trending

article thumbnail

GSK nears $1bn deal for biotech developing drug for rare tumour

Financial Times M&A

IDRx tests treatment for digestive system cancer that affects 4,000 to 6,000 people a year in US

76
article thumbnail

How biopharmaceutical leaders optimize their portfolio strategies

Mckinsey and Company

Leading biopharmaceutical companies manage their clinical pipelines to optimize for risk and reward. Heres how.

57
article thumbnail

Apollo’s Leon Black in talks over Efune’s Telegraph bid

Financial Times M&A

Billionaire in discussions over backing 550mn deal for British broadsheet

64
article thumbnail

Charting the path to patients

Mckinsey and Company

Careful development of asset strategy across the pharmaceutical R&D pipeline is increasingly important in embracing opportunities for innovation.

57
article thumbnail

Statement of Cash Flows vs. Cash Flow Statement

Speaker: Wayne Spivak - President and Chief Financial Officer of SBA * Consulting LTD, Industry Writer, and Public Speaker

The old adages that "cash is king" and "you can’t spend profits" still hold true today. But however well-known these sayings might be, it requires a change in mindset to properly implement a cash flow management system that predicts your business's runaway as accurately as possible. Key to this new mindset is understanding the difference between the Statement of Cash Flows, a historical look at the source and uses of cash, and the Cash Flow Statement, which uses transaction history and forward-l

article thumbnail

Piers Morgan targets US after YouTube venture buyout from Rupert Murdoch’s News UK

Financial Times M&A

British presenters production company to acquire his Uncensored show

58
article thumbnail

Business Valuation for Selling an Advertising Agency

Peak Business Valuation

Do you own an advertising agency ? If so, selling your advertising agency is a great way to profit from previous work. A valuation for selling an advertising agency will set you on a path to a profitable sale. An advertising agency valuation provides you with the information you need to make strategic decisions while selling your agency. Peak Business Valuation is a trusted appraiser.

article thumbnail

AbbVie’s head of genomics research on the transformative power of AI

Mckinsey and Company

Howard Jacob, vice president of genomics research and head of data integration at AbbVie, shares his view on the potential of personalized data, AI, and machine learning to prevent and cure disease.

54
article thumbnail

Group Alleges $10M 'Sham' In Fla. Plant-Based Co. Stock Deal

Law 360 M&A

A Canadian investment group has sued two Delaware corporations in Florida federal court over a "sham" stock deal, alleging it was fraudulently induced to sell its plant-based food technology company and later cheated out of $10 million worth of cash and common stock it was promised.

article thumbnail

Mastering Intent Data: Understanding its Importance & Best Practices

Speaker: Joe Apfelbaum, CEO of Ajax Union

In this webinar, Joe Apfelbaum, CEO of Ajax Union and business strategist, will take you through the ABCs of intent data. You'll learn how to effectively use it to drive business results, with practical tips on how to leverage both company and contact intent data to maximize your marketing efforts. Whether you're a seasoned marketer or just getting started, this webinar is a must-attend for anyone looking to stay ahead in the ever-evolving world of digital marketing.

article thumbnail

This may be the greatest source of risk

Norman Marks

I think this is probably the #1 risk, but nobody talks about it in surveys. Its the risk of poor decisions. Who can argue that this is not only likely to be devastating to any business, but it is not uncommon?

article thumbnail

UnitedHealth Wants $3.3B Amedisys Deal Challenge Tossed

Law 360 M&A

UnitedHealth Group and Amedisys Inc. asked a Maryland federal court Wednesday to toss a challenge of their planned $3.3 billion merger, contending that federal and state enforcers are refusing to say what "local" home health and hospice service markets would be hurt by the deal.

article thumbnail

Proxy Contests: How Often Are Compensation Issues Raised?

John Jenkins

This recent alert from Compensation Advisory Partners updates research from 2015 on how often and when activist investors raise issues with executive pay during proxy contests.

45
article thumbnail

Colo. Judge Certifies National Class Of Senior Care Investors

Law 360 M&A

A Colorado federal judge on Wednesday certified a nationwide class of stockholders in a securities suit alleging a senior health care company made misleading statements in an initial public offering that later caused stock prices to tank after a government audit exposed the falsehoods.

52
article thumbnail

Boosting biopharma R&D performance with a next-generation technology stack

Mckinsey and Company

A modern, well-designed tech stack can unlock the potential of AI, automation, and data and their promised benefits to R&D productivity.

article thumbnail

Shoppers Say Kroger Merger Suit Still Alive After Nixed Deal

Law 360 M&A

Consumers challenging the abandoned merger between Kroger Co. and Albertsons urged a California federal court not to toss their case despite two court injunctions against the deal, arguing that they have effectively prevailed on their antitrust claims and should get an injunction and attorney fees.

52
article thumbnail

Putting people at the center of the R&D talent model in life sciences

Mckinsey and Company

Rapid advancements in science and technology are challenging pharma and biotech companies approaches to talent. What R&D skills do they need today, and how can they sustain this workforce?

article thumbnail

T-Mobile-UScellular Deal Won't Hurt Wireless Market, FCC Told

Law 360 M&A

T-Mobile's $4.4 billion plan to buy spectrum and lease cell towers from UScellular appears likely to benefit consumers, a free-market think tank told the Federal Communications Commission as public interest groups continue to fight the deal.

article thumbnail

Building a shared vision for pharma R&D–supplier partnerships

Mckinsey and Company

Pharma R&D leaders and their suppliers see transparency as a key to unlocking more effective collaborations and cost efficiencies.

44
article thumbnail

3 Firms Steer Galapagos' Plan To Spin Off New Drug Company

Law 360 M&A

Belgian biotechnology firm Galapagos NV said Wednesday that it will spin off certain operations into a second company focused on developing innovative medicines with about 2.45 billion ($2.5 billion) in cash to start, while Galapagos in turn focuses on cell therapies, through a deal guided by three law firms.

52
article thumbnail

External innovation: Biopharma dealmaking to boost R&D productivity

Mckinsey and Company

Top-performing pharma companies over the past decade have relied on a short list of critical dealmaking behaviors that drive high external innovation productivity.

44
article thumbnail

NY Banking Brief: All The Notable Legal Updates In Q4

Law 360 M&A

In 2024's final quarter, the New York State Department of Financial Services published guidance on mitigating the rising cybersecurity risks of artificial intelligence and remote technology workers with North Korean ties, and the state attorney general launched an antitrust investigation into Capital One's proposed Discover merger, say attorneys at Haynes Boone.

Banking 52
article thumbnail

Avid Bioservices Files Investor Presentation Highlighting Value Maximizing Transaction with GHO and Ampersand

Benzinga

TUSTIN, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO ) ("Avid" or the "Company"), a dedicated biologics contract development and manufacturing organization ("CDMO") working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today posted an investor presentation in connection with its pending transaction with GHO Capital Partners LLP ("GHO") and Ampersand Capital Partners ("Ampe

article thumbnail

Jones Day, Ropes & Gray Build $795M Deal For Simple Mills

Law 360 M&A

Packaged bakery food producer Flowers Foods Inc., advised by Jones Day, on Wednesday announced plans to acquire better-for-you snack brand Simple Mills, led by Ropes & Gray LLP, in a $795 million cash deal.

52
article thumbnail

Investing Principles: Lessons Learned from 20 Years of Wins, Losses, and Strikeouts

Brian DeChesare

Ive said before that nothing on this site is meant to be investment advice. That said, my annual investment/market updates always get a lot of traffic, so I thought it might be interesting to follow up on this years update with more of an advice article. If youre reading this right now, youre probably much younger than me. Ive now been working and investing for ~20 years and have made dozens of mistakes along the way.

article thumbnail

Wilson Sonsini, Cooley Lead $621M Take-Private Of Accolade

Law 360 M&A

Private equity-backed healthcare company Transcarent, advised by Wilson Sonsini Goodrich & Rosati PC, and personalized healthcare company Accolade, led by Cooley LLP, on Wednesday announced plans to merge in a $621 million deal that will result in Accolade becoming a private company.

Equity 52
article thumbnail

Comment on Appraisal Industry Outlook Under Trump Administration by ohiobeasttwoonesix

Appraisers Blog

Business Insider The hidden middlemen who cost homebuyers $12 billion and counting If you bought a home after 2009, your appraisal fee almost certainly included hundreds of dollars for a middleman you’ve likely never heard… [link] this is what they call public trust…revaa is now a partner of taf…i cant stop laughing 2

article thumbnail

Boston Scientific Paying Up To $664M For Bolt Medical

Law 360 M&A

Boston Scientific Corp. said Wednesday it plans to acquire the remaining stake it does not own in Bolt Medical Inc., the developer of a proprietary laser-based treatment for coronary and peripheral artery disease, for up to $664 million.

52
article thumbnail

Comment on Appraisal Industry Outlook Under Trump Administration by Bill Johnson

Appraisers Blog

On bias & discrimination, the Trump administration is likely to reverse any actions seen as threatening the integrity of appraisals.

article thumbnail

Skadden-Led Dutch Chips Maker To Buy $625M Car Tech Co.

Law 360 M&A

Car chips maker NXP Semiconductors NV has agreed to acquire Austrian automotive technology company TTTech Auto in an all-cash transaction for $625 million to strengthen its automotive business, in a deal guided by Skadden Arps Slate Meagher & Flom LLP.